ReviewHeart failure reviews2021
Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging.
Review in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Cardiac magnetic resonance imaging for discrimination of hypertensive heart disease and hypertrophic cardiomyopathy: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Left atrial dysfunction in different morphologic phenotypes of hypertrophic cardiomyopathy: a cardiac magnetic resonance feature tracking study.Quantitative imaging in medicine and surgery · 2026Article
- Novel compound heterozygous mutations inFrontiers in cardiovascular medicine · 2026Article
- Cardiomyocyte hypertrophy co-localizes with accumulation of hyaluronan in cMyBPC+/- mice hearts.PloS one · 2026Article
- Right coronary artery originated from left coronary sinus associated with children hypertrophic cardiomyopathy: report of two cases and literature review.Open medicine (Warsaw, Poland) · 2026Article
- Diffuse hypertrophic obstructive cardiomyopathy complicated by apical ventricular aneurysm and excessive left ventricular trabeculation: a case report.Frontiers in cardiovascular medicine · 2026Article
- The Evolving Role of Cardiac Imaging in Hypertrophic Cardiomyopathy: Diagnosis, Prognosis, and Clinical Practice.Biomedicines · 2025Review
- Complementary classification of hypertrophic cardiomyopathy using unsupervised cluster analysis on left ventricular function.Scientific reports · 2025Article
- Unmasking yamaguchi syndrome: A rare case of apical hypertrophic cardiomyopathy in a young African - American male.Bioinformation · 2025Article
- Twin Phenomena of Hypertrophic Cardiomyopathy: A Reported Case Series.Anatolian journal of cardiology · 2024Review
- The D75N and P161S Mutations in the C0-C2 Fragment of cMyBP-C Associated with Hypertrophic Cardiomyopathy Disturb the Thin Filament Activation, Nucleotide Exchange in Myosin, and Actin-Myosin Interaction.International journal of molecular sciences · 2024Article
- An overview of the treatments for hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2024Review
- Genetics-diet crossroads: Unveiling new insights into hypertrophic cardiomyopathy.Journal of molecular and cellular cardiology plus · 2023Article
- Genetic architecture of spatial electrical biomarkers for cardiac arrhythmia and relationship with cardiovascular disease.Nature communications · 2023Article
- Cardiac Resynchronization Therapy and Hypertrophic Cardiomyopathy: A Comprehensive Review.Biomedicines · 2023Review
- Improvement in coronary microvascular dysfunction evaluated by cardiac magnetic resonance in patients with hypertrophic obstructive cardiomyopathy after transapical beating-heart septal myectomy.Frontiers in cardiovascular medicine · 2023Article
- Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.Cardiology and therapy · 2022Review
- MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis.Cell death & disease · 2022Article
- Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis.ESC heart failure · 2022Article
- Recent Non-Invasive Parameters to Identify Subjects at High Risk of Sudden Cardiac Death.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common cardiovascular disease with genetic transmission, characterized by the hypertrophy of any segment of the left ventricle (LV), not totally explained by improper loading conditions, with LV systolic function preserved, increased, or reduced. The histopathological mechanism involved in HCM refers to the primary injury of the myocardium, as follows: disorganized array of myocytes, extracellular matrix modification, microvascular dysfunction, with subsequent appearance of myocardial fibrosis. Multiple sarcomere proteins mutations are responsible for HCM, but two of them are involved in 70% of the cases of HCM: β-myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3). The development of new genetic techniques involving genome editing is promising to discover a gene therapy for patients with HCM. Clinical presentation may differ from asymptomatic to sudden cardiac death (SCD), the last one targeting younger adults. In this case, the diagnosis and evaluation of SCD risk factors is extremely important. The common method of diagnosis is transthoracic echocardiography, but cardiac magnetic resonance (CMR) imaging represents "gold standard" in the evaluation of HCM patients. Treatment includes pharmacological therapy, surgery, alcohol ablation, and not least SCD prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.